Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 09, 2026
DataAggregated Company Financials
Companies64
  • 7D-1.7%
  • 3M3.4%
  • 1Y9.6%
  • YTD-14.1%

Over the last 7 days, the Life Sciences industry has dropped 1.4%, driven by Thermo Fisher Scientific declining 4.9%. Over the past 12 months, the industry was up 10%. Earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 09 Jun 2026US$586.3bUS$150.6bUS$13.8b38.4x42.6x3.9x
Thu, 07 May 2026US$555.7bUS$150.2bUS$14.0b33.7x39.7x3.7x
Sat, 04 Apr 2026US$561.8bUS$147.8bUS$14.1b37.2x39.9x3.8x
Mon, 02 Mar 2026US$599.3bUS$147.9bUS$14.0b35.2x42.9x4.1x
Wed, 28 Jan 2026US$696.9bUS$145.9bUS$12.4b35.8x56.3x4.8x
Fri, 26 Dec 2025US$664.7bUS$145.8bUS$12.5b35.3x53.3x4.6x
Sun, 23 Nov 2025US$666.0bUS$145.6bUS$12.4b36.2x53.8x4.6x
Tue, 21 Oct 2025US$636.0bUS$144.3bUS$14.6b32.5x43.7x4.4x
Thu, 18 Sep 2025US$571.0bUS$144.3bUS$14.6b29.7x39.2x4x
Sat, 16 Aug 2025US$580.5bUS$144.2bUS$14.5b29x40.1x4x
Mon, 14 Jul 2025US$551.9bUS$142.9bUS$9.1b36.9x60.5x3.9x
Wed, 11 Jun 2025US$525.9bUS$142.9bUS$9.2b36.7x57.4x3.7x
Fri, 09 May 2025US$511.1bUS$142.7bUS$9.6b35x53.2x3.6x
Sun, 06 Apr 2025US$509.0bUS$142.5bUS$9.9b33.4x51.2x3.6x
Tue, 04 Mar 2025US$605.1bUS$143.0bUS$9.7b37.7x62.4x4.2x
Thu, 30 Jan 2025US$705.6bUS$142.4bUS$10.2b41.1x69.1x5x
Sat, 28 Dec 2024US$659.4bUS$142.4bUS$10.2b44.7x64.5x4.6x
Mon, 25 Nov 2024US$656.8bUS$142.4bUS$10.4b44.1x63.4x4.6x
Wed, 23 Oct 2024US$727.8bUS$140.7bUS$8.2b36.7x88.7x5.2x
Fri, 20 Sep 2024US$744.1bUS$141.8bUS$8.5b38.1x87.6x5.2x
Sun, 18 Aug 2024US$738.6bUS$141.5bUS$8.4b38.8x88.3x5.2x
Tue, 16 Jul 2024US$685.9bUS$141.2bUS$12.2b41x56.2x4.9x
Thu, 13 Jun 2024US$706.7bUS$141.3bUS$12.2b37.6x58x5x
Sat, 11 May 2024US$719.0bUS$141.5bUS$12.7b38.6x56.8x5.1x
Mon, 08 Apr 2024US$727.9bUS$142.1bUS$12.8b43.1x56.9x5.1x
Wed, 06 Mar 2024US$747.1bUS$142.1bUS$12.8b44.3x58.2x5.3x
Fri, 02 Feb 2024US$710.9bUS$147.6bUS$12.5b38.7x56.8x4.8x
Sun, 31 Dec 2023US$700.9bUS$153.8bUS$14.2b37.8x49.2x4.6x
Tue, 28 Nov 2023US$642.9bUS$153.8bUS$14.0b34.5x45.9x4.2x
Thu, 26 Oct 2023US$578.1bUS$153.9bUS$10.8b29.9x53.6x3.8x
Sat, 23 Sep 2023US$670.2bUS$154.6bUS$11.2b31.2x59.8x4.3x
Mon, 21 Aug 2023US$702.8bUS$154.6bUS$11.2b32.5x62.7x4.5x
Wed, 19 Jul 2023US$703.7bUS$155.5bUS$12.7b29.6x55.5x4.5x
Fri, 16 Jun 2023US$690.5bUS$152.4bUS$12.5b29.3x55.2x4.5x
Price to Earnings Ratio

55.2x


Total Market Cap: US$690.5bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.6x which is lower than its 3-year average PE of 56.4x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.2% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-2.73%
Healthcare1.94%
Life Sciences-1.75%
Clinical Research and Equipment-1.75%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DHR DanaherUS$183.532.0%
+US$2.6b		-7.9%PE35.3x
ICLR ICONUS$152.2410.3%
+US$1.1b		9.0%PE50.8x
AVTR AvantorUS$9.695.4%
+US$341.4m		-28.0%PS1x
TECH Bio-TechneUS$52.653.7%
+US$291.2m		5.6%PE75.3x
WST West Pharmaceutical ServicesUS$319.751.1%
+US$243.7m		42.9%PE41.6x

Latest News

WST
US$319.75
West Pharmaceutical Services
7D
1.1%
1Y
42.9%
TMO
US$469.63
Thermo Fisher Scientific
7D
-4.9%
1Y
15.0%
A
US$132.69
Agilent Technologies
7D
-2.4%
1Y
13.7%
Narrative Update • Jun 06

A: AI Partnerships And New Diagnostics Offer Compelling Future Upside Potential

Analysts have adjusted their price target on Agilent Technologies slightly to $161.00. This reflects updated assumptions around discount rate, long term revenue growth, profit margins and future P/E expectations.
TECH
US$52.65
Bio-Techne
7D
3.7%
1Y
5.6%
MEDP
US$457.90
Medpace Holdings
7D
1.4%
1Y
53.5%
ADPT
US$16.70
Adaptive Biotechnologies
7D
9.7%
1Y
59.8%
ICLR
US$152.24
ICON
7D
10.3%
1Y
9.0%
IQV
US$183.69
IQVIA Holdings
7D
-1.7%
1Y
19.2%
ILMN
US$158.04
Illumina
7D
-3.9%
1Y
86.0%
TEM
US$48.59
Tempus AI
7D
-8.0%
1Y
-27.4%
BIO
US$291.31
Bio-Rad Laboratories
7D
-4.6%
1Y
29.1%
Narrative Update • Jun 04

BIO: Activist Pressure And Buybacks Will Shape Future Value Realization

Analysts have reaffirmed their $320.00 price target for Bio-Rad Laboratories, citing adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the main factors behind the updated view. What's in the News Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories after the stock declined more than 70% from its late 2021 peak, and is publicly pushing for improvements in the share price and company performance.
WAT
US$363.34
Waters
7D
-3.9%
1Y
4.3%
Narrative Update • Jun 03

WAT: New Omics Platforms And Buybacks Will Support Future Upside

Analysts have trimmed their price target for Waters to $460, reflecting slightly higher assumed discount rates, modestly adjusted long term revenue growth and profit margin expectations, and a lower future P/E multiple in their updated models. What's in the News Waters launched the Cyclic IMS P20 Mass Spectrometer, a structural and spatial omics platform using multipass Cyclic Ion Mobility Spectrometry and advanced fragmentation and imaging techniques, aimed at earlier detection of disease signals and more detailed molecular visualization.
MTD
US$1,138.88
Mettler-Toledo International
7D
-3.8%
1Y
-4.7%
Narrative Update • Jun 03

MTD: Automation And Emerging Markets Will Support EPS Upside Despite Geopolitical Risks

Analysts have trimmed their average price target for Mettler-Toledo International from about $1,344.50 to roughly $1,327.83. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations.
CRL
US$186.44
Charles River Laboratories International
7D
2.4%
1Y
26.4%
Narrative Update • Jun 03

CRL: Rich Multiple And Margin Pressure Will Likely Cap AI Upside

Analysts have lifted the fair value estimate for Charles River Laboratories International by about $6.81 per share to $154.56, citing a more supportive regulatory backdrop for cross-border biotech work and expectations that divesting lower margin operations could improve overall earnings quality. Analyst Commentary Recent research commentary on Charles River Laboratories International has leaned more constructive on the regulatory backdrop for cross-border biotech work and on the potential earnings mix shift from divesting lower margin activities.
AVTR
US$9.69
Avantor
7D
5.4%
1Y
-28.0%
DHR
US$183.53
Danaher
7D
2.0%
1Y
-7.9%